How have EUCRU shares performed in 2024?

Eucrates Biomedical Acquisition's stock was trading at $10.02 at the beginning of the year. Since then, EUCRU stock has increased by 0.0% and is now trading at $10.02. View the best growth stocks for 2024 here .

How do I buy shares of Eucrates Biomedical Acquisition?

Shares of EUCRU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:EUCRU

Eucrates Biomedical Acquisition (EUCRU) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free EUCRU Stock Alerts

$10.02

+0.01 (+0.10%)

(As of 04/26/2023)

Compare

Today's Range: $10.01
▼
$10.02
50-Day Range: $10.02
▼
$10.02
52-Week Range: $9.76
▼
$10.66

Volume: 21,500 shs
Average Volume: 1,921 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Eucrates Biomedical Acquisition alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Eucrates Biomedical Acquisition

Eucrates Biomedical Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses to identify and acquire a business in the biomedical or healthcare-related industries in North America and Europe. The company was incorporated in 2020 and is based in New York, New York.

EUCRU Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EUCRU Stock News Headlines

April 11, 2023 | seekingalpha.com

Eucrates Biomedical Acquisition announces liquidation

April 11, 2023 | finance.yahoo.com

Eucrates Biomedical Acquisition Corp. Announces Liquidation

April 19, 2024 | InvestorPlace (Ad)

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

January 30, 2023 | finance.yahoo.com

Biomedical Sensors Market will surpass USD 21.3 billion by 2030 at a CAGR of 16% till 2030 : GreyViews

January 25, 2023 | mirror.co.uk

Love Island 2023: First contestant revealed as stunning biomedical student Tanya

January 11, 2023 | money.usnews.com

Biomedical Engineer

October 6, 2022 | markets.businessinsider.com

Centerline Biomedical announces Gulam Khan as Chief Executive Officer

See More Headlines

Receive EUCRU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eucrates Biomedical Acquisition and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Finance
Industry: Shell Companies
Sub-Industry: N/A
Current Symbol: OTCMKTS:EUCRU
CUSIP: N/A
CIK: 1822929
Web: N/A
Phone: N/A
Fax: N/A
Employees: 4
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Parag Phoolchand Saxena MBA (Age 66)
MS, CEO & Director
Dr. Evangelos Vergetis (Age 41)
Pres, COO & Director
Mr. Gonzalo Cordova CFA (Age 67)
Chief Financial Officer
Mr. Shrikant Sathe (Age 66)
Sr. VP

Key Competitors

View All Competitors

EUCRU Stock Analysis - Frequently Asked Questions

How have EUCRU shares performed in 2024?: Eucrates Biomedical Acquisition's stock was trading at $10.02 at the beginning of the year. Since then, EUCRU stock has increased by 0.0% and is now trading at $10.02.
View the best growth stocks for 2024 here.
How do I buy shares of Eucrates Biomedical Acquisition?: Shares of EUCRU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:EUCRU) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial